Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status approved; investigational
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 65044-7183; 62756-233; 38779-0191; 51552-0304; 51927-1726; 62991-1173; 39822-1055; 55500-0001; 63622-0123; 63622-0124; 63622-0125; 0469-3051; 39635-0003; 45932-0008; 55150-365
UNII 7XU7A7DROE
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3; 30652-87-0
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000094%
Urethral disorder20.07.01.002--Not Available
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasodilatation23.06.05.006; 24.03.02.003--Not Available
Venoocclusive liver disease12.02.09.039; 24.04.07.002; 09.01.06.002--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000254%
Hypoacusis04.02.01.006--
General physical health deterioration08.01.03.0180.000188%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000141%Not Available
Hyperfibrinogenaemia01.01.02.014--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Haemodynamic instability24.03.02.0060.000094%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Nodule08.03.05.002--Not Available
Haemorrhage24.07.01.002--Not Available
Procedural complication12.02.05.005--
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene